rachel_ABQ said:FDA inspection results for compounding pharmacies selling compounded supply: you can look up any 503B facility's FDA inspection history on the FDA…
Price comparison for compounded supply across sources I've used:
| Source | Monthly Cost | Type | Purity Verified |
|---|---|---|---|
| Brand (Ozempic) | $958 | FDA-approved | N/A (pharma) |
| 503B Compounding | $138 | cGMP compounded | Yes (in-house) |
| 503A Compounding | $108 | Patient-specific | Varies |
| Research peptide | $48 | Not for human use | Often Janoshik |
I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.
alex_tucson said:Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces…
Thank you — that is the clearest version of this I have read, and I have read a lot of them. Adding it to my notes with a link back to this thread.
rachel_ABQ said:FDA inspection results for compounding pharmacies selling compounded supply: you can look up any 503B facility's FDA inspection history on the FDA…
Compounded has been just as effective for me. If compounded supply is the concern, the COA from my 503B pharmacy shows 99.1% purity. Verified by Janoshik.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsPharmHunterJen said:Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…
Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.
Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide partially resolved shortage, tirzepatide still in shortage. This directly impacts compounding availability.